European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
10 2020
Historique:
received: 21 05 2020
revised: 02 07 2020
accepted: 19 07 2020
pubmed: 2 9 2020
medline: 22 1 2021
entrez: 2 9 2020
Statut: ppublish

Résumé

Smoking cessation after a cancer diagnosis is associated with improved overall survival. Few studies have reported oncologists' cessation practice patterns, but differences between the curative and palliative settings have not been described. We aimed to study the oncologist's perceptions on patients' tobacco use, current practices and barriers to providing smoking cessation support, while distinguishing between treatment with curative (C) and palliative (P) intent. In 2019, an online 34-item survey was sent to approximately 6235 oncologists from 16 European countries. Responses were descriptively reported and compared by treatment setting. Responses from 544 oncologists were included. Oncologists appeared to favour addressing tobacco in the curative setting more than in the palliative setting. Oncologists believe that continued smoking impacts treatment outcomes (C: 94%, P: 74%) and that cessation support should be standard cancer care (C: 95%, P: 63%). Most routinely assess tobacco use (C: 93%, P: 78%) and advise patients to stop using tobacco (C: 88%, P: 54%), but only 24% (P)-39% (C) routinely discuss medication options, and only 18% (P)-31% (C) provide cessation support. Hesitation to remove a pleasurable habit (C: 13%, P: 43%) and disbelieve on smoking affecting outcomes (C: 3%, P: 14%) were disparate barriers between the curative and palliative settings (p < 0.001), but dominant barriers of time, resources, education and patient resistance were similar between settings. Oncologists appear to favour addressing tobacco use more in the curative setting; however, they discuss medication options and/or provide cessation support in a minority of cases. All patients who report current smoking should have access to evidence-based smoking cessation support, also patients treated with palliative intent given their increasing survival.

Sections du résumé

BACKGROUND
Smoking cessation after a cancer diagnosis is associated with improved overall survival. Few studies have reported oncologists' cessation practice patterns, but differences between the curative and palliative settings have not been described. We aimed to study the oncologist's perceptions on patients' tobacco use, current practices and barriers to providing smoking cessation support, while distinguishing between treatment with curative (C) and palliative (P) intent.
METHODS
In 2019, an online 34-item survey was sent to approximately 6235 oncologists from 16 European countries. Responses were descriptively reported and compared by treatment setting.
RESULTS
Responses from 544 oncologists were included. Oncologists appeared to favour addressing tobacco in the curative setting more than in the palliative setting. Oncologists believe that continued smoking impacts treatment outcomes (C: 94%, P: 74%) and that cessation support should be standard cancer care (C: 95%, P: 63%). Most routinely assess tobacco use (C: 93%, P: 78%) and advise patients to stop using tobacco (C: 88%, P: 54%), but only 24% (P)-39% (C) routinely discuss medication options, and only 18% (P)-31% (C) provide cessation support. Hesitation to remove a pleasurable habit (C: 13%, P: 43%) and disbelieve on smoking affecting outcomes (C: 3%, P: 14%) were disparate barriers between the curative and palliative settings (p < 0.001), but dominant barriers of time, resources, education and patient resistance were similar between settings.
CONCLUSION
Oncologists appear to favour addressing tobacco use more in the curative setting; however, they discuss medication options and/or provide cessation support in a minority of cases. All patients who report current smoking should have access to evidence-based smoking cessation support, also patients treated with palliative intent given their increasing survival.

Identifiants

pubmed: 32871527
pii: S0959-8049(20)30420-2
doi: 10.1016/j.ejca.2020.07.020
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

99-108

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement The authors have declared no conflicts of interest.

Auteurs

Jeroen W G Derksen (JWG)

Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Graham W Warren (GW)

Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC, USA.

Karin Jordan (K)

Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany.

Stefan Rauh (S)

Department of Oncology, Centre Hospitalier Emile Mayrisch, Esch-sur-Alzette, Luxembourg.

Ruth Vera García (R)

Department of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain.

Deirdre O'Mahony (D)

Department of Medical Oncology, Cork University Hospital, Cork, Ireland.

Samreen Ahmed (S)

Department of Medical Oncology, University Hospitals of Leicester, Leicester, UK.

Peter Vuylsteke (P)

Department of Medical Oncology, UCLouvain, CHU Namur, Belgium; Faculty of Medicine, University of Botswana, Gaborone, Botswana.

Sinisa Radulovic (S)

Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.

Nikolaos Tsoukalas (N)

Department of Oncology, 401 General Military Hospital of Athens, Athens, Greece.

Piotr J Wysocki (PJ)

Department of Oncology, Jagiellonian University - Medical College, Cracow, Poland.

Markus Borner (M)

Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Alvydas Cesas (A)

Department of Medical Oncology, Klaipeda University Hospital, Klaipeda, Lithuania.

Anneli Elme (A)

Department of Oncology and Hematology, North Estonia Medical Centre Foundation, Tallinn, Estonia.

Heikki Minn (H)

Department of Oncology, Turku University Hospital, Turku, Finland.

Gustav J Ullenhag (GJ)

Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; Department of Immunology, Genetics and Pathology, Science of Life Laboratory, Uppsala University, Uppsala, Sweden.

Jeanine M L Roodhart (JML)

Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Miriam Koopman (M)

Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Anne M May (AM)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Electronic address: a.m.may@umcutrecht.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH